Rhythm Pharmaceuticals (RYTM) Competitors $65.19 -0.03 (-0.05%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$65.00 -0.19 (-0.28%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, ROIV, and LNTHShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus Rhythm Pharmaceuticals (NASDAQ:RYTM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Does the media prefer RYTM or TEVA? In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 13 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.47 beat Teva Pharmaceutical Industries' score of 1.23 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 14 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, RYTM or TEVA? Rhythm Pharmaceuticals has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M31.67-$184.68M-$4.35-14.99Teva Pharmaceutical Industries$16.54B1.06-$1.64B-$1.45-10.70 Do insiders and institutionals hold more shares of RYTM or TEVA? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor RYTM or TEVA? Teva Pharmaceutical Industries received 1026 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 68.06% of users gave Rhythm Pharmaceuticals an outperform vote while only 67.84% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes30968.06% Underperform Votes14531.94% Teva Pharmaceutical IndustriesOutperform Votes133567.84% Underperform Votes63332.16% Do analysts recommend RYTM or TEVA? Rhythm Pharmaceuticals presently has a consensus target price of $74.92, indicating a potential upside of 14.93%. Teva Pharmaceutical Industries has a consensus target price of $23.43, indicating a potential upside of 51.05%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has more risk and volatility, RYTM or TEVA? Rhythm Pharmaceuticals has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Is RYTM or TEVA more profitable? Teva Pharmaceutical Industries has a net margin of -9.91% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Teva Pharmaceutical Industries -9.91%42.46%6.65% SummaryTeva Pharmaceutical Industries beats Rhythm Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.12B$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-15.067.4422.4418.48Price / Sales31.67242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book22.716.516.774.25Net Income-$184.68M$143.21M$3.22B$248.23M7 Day Performance3.53%1.98%1.49%0.89%1 Month Performance30.38%6.89%4.00%3.53%1 Year Performance57.35%-2.52%16.21%5.08% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.6999 of 5 stars$65.190.0%$74.92+14.9%+64.0%$4.12B$130.13M-15.06140Upcoming EarningsPositive NewsTEVATeva Pharmaceutical Industries3.2363 of 5 stars$13.30-2.6%$23.43+76.2%+10.5%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst RevisionPositive NewsITCIIntra-Cellular Therapies0.8841 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4406 of 5 stars$20.07+0.1%$39.17+95.2%-23.6%$13.28B$21.53B11.531,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8458 of 5 stars$13.68+0.1%$17.00+24.3%-5.3%$11.42B$311.31B21.7824,800Upcoming EarningsASNDAscendis Pharma A/S2.3244 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Positive NewsMRNAModerna4.2602 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageVTRSViatris1.8335 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6831 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.1666 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9711 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive News Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Roivant Sciences Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
